文献速递膀胱癌与上尿路尿路上皮癌

临床前膀胱癌模型中克拉屈滨较吉西他滨具有更优治疗窗

Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models.
PubMed 文献 · Eur Urol Oncol · 2024-05-16

研究在膀胱癌体外与体内临床前模型中头对头比较克拉屈滨与吉西他滨,并以计算机模拟分析补充。结果显示吉西他滨细胞毒性更高,尤其对非恶性细胞;克拉屈滨耐受性明显更好,抗癌疗效明显更优,并在小鼠模型中获得完全缓解或治愈,吉西他滨可耐受方案均未达到。

要点

  • 体外模型中吉西他滨细胞毒性高于克拉屈滨,尤其对非恶性细胞。
  • 患者来源异种移植模型中克拉屈滨耐受性明显优于吉西他滨。
  • 克拉屈滨抗癌疗效明显更优,且观察到完全缓解或治愈,吉西他滨可耐受方案均未达到。

核心结论

  • 克拉屈滨较吉西他滨具有更好的治疗窗,进一步支持其作为膀胱癌药物重定位候选。
  • 作者认为克拉屈滨单药或联合方案可能优于吉西他滨用于膀胱癌治疗。

研究设计与样本

  • 在膀胱癌临床前体外与体内模型中进行克拉屈滨与吉西他滨的头对头比较,并以计算机模拟分析补充。
  • 体内使用患者来源异种移植模型,克拉屈滨经口服或腹腔给药,吉西他滨经腹腔给药。
  • 体外实验比较两种抗代谢药对包括角质形成细胞和内皮细胞在内的多种细胞的细胞毒性。

主要发现

  • 体外数据显示两种抗代谢药之间存在明显相关性,吉西他滨细胞毒性更高,尤其对包括角质形成细胞和内皮细胞在内的几种非恶性细胞类型。
  • 在膀胱癌患者来源异种移植模型中,克拉屈滨(口服或腹腔给药)的耐受性明显优于吉西他滨(腹腔给药)。
  • 克拉屈滨抗癌疗效明显更优,即使在为吉西他滨优化的给药方案下亦然。
  • 克拉屈滨观察到完全缓解或治愈,而任何可耐受的吉西他滨方案均未达到完全缓解或治愈。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current standard-of-care systemic therapy options for locally advanced and metastatic bladder cancer (BC), which are predominantly based on cisplatin-gemcitabine combinations, are limited by significant treatment failure rates and frailty-based patient ineligibility. We previously addressed the urgent clinical need for better-tolerated BC therapeutic strategies using a drug screening approach, which identified outstanding antineoplastic activity of clofarabine in preclinical models of BC. To further assess clofarabine as a potential BC therapy component, we conducted head-to-head comparisons of responses to clofarabine versus gemcitabine in preclinical in vitro and in vivo models of BC, complemented by in silico analyses. In vitro data suggest a distinct correlation between the two antimetabolites, with higher cytotoxicity of gemcitabine, especially against several nonmalignant cell types, including keratinocytes and endothelial cells. Accordingly, tolerance of clofarabine (oral or intraperitoneal application) was distinctly better than for gemcitabine (intraperitoneal) in patient-derived xenograft models of BC. Clofarabine also exhibited distinctly superior anticancer efficacy, even at dosing regimens optimized for gemcitabine. Neither complete remission nor cure, both of which were observed with clofarabine, were achieved with any tolerable gemcitabine regimen. Taken together, our findings demonstrate that clofarabine has a better therapeutic window than gemcitabine, further emphasizing its potential as a candidate for drug repurposing in BC. PATIENT SUMMARY: We compared the anticancer activity of clofarabine, a drug used for treatment of leukemia but not bladder cancer, and gemcitabine, a drug currently used for chemotherapy against bladder cancer. Using cell cultures and mouse models, we found that clofarabine was better tolerated and more efficacious than gemcitabine, and even cured implanted tumors in mouse models. Our results suggest that clofarabine, alone or in combination schemes, might be superior to gemcitabine for the treatment of bladder cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gutmann M, Ertl IE, Herek P, et al. Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models. Eur Urol Oncol. 2024. PMID: 38755094. doi:10.1016/j.euo.2024.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。